- Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
-
Kim D, Danpanichkul P, Wijarnpreecha K, Cholankeril G, Ahmed A
- KMID: 2560102
- Clin Mol Hepatol.
- 2024 Oct;30(4):982-986.
- doi: 10.3350/cmh.2024.0691
-
- CITED
-
- Close
- SHARE
-
- Close
- Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
-
Wijarnpreecha K, Aby ES, Ahmed A, Kim D
- KMID: 2514762
- Clin Mol Hepatol.
- 2021 Apr;27(2):221-235.
- doi: 10.3350/cmh.2020.0239
Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations
-
Danpanichkul P, Suparan K, Prasitsumrit V, Ahmed A, Wijarnpreecha K, Kim D
- KMID: 2563408
- Clin Mol Hepatol.
- 2025 Jan;31(1):74-89.
- doi: 10.3350/cmh.2024.0631
One-third of adults across the globe exhibit metabolic dysfunction-associated steatotic liver disease (MASLD)―formerly known as nonalcoholic fatty liver disease (NAFLD). To date, MASLD is the fastest-growing etiology of chronic liver... -
- CITED
-
- Close
- SHARE
-
- Close
- Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023
-
Kim D, Manikat R, Wijarnpreecha K, Cholankeril G, Ahmed A
- KMID: 2560084
- Clin Mol Hepatol.
- 2024 Oct;30(4):756-770.
- doi: 10.3350/cmh.2024.0318
Backgrounds/Aims: The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve. We estimated the sex- and race/ethnicity-based... -
- CITED
-
- Close
- SHARE
-
- Close
